Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 270 pages

Showing 251 - 270


lymphoma

‘Reprogrammed’ Treatment-Resistant Lymphomas Respond to Azacitidine

A phase I clinical trial showed diffuse large B-cell lymphomas resistant to chemotherapy can be reprogrammed to respond to treatment after being pretreated with drug azacitidine (Vidaza), according to a study published in Cancer Discovery. Patients whose lymphomas recur after initial chemotherapy...

lymphoma

Burkitt Lymphoma Survival Outcomes Improve for Younger Patients

According to a new study published in the journal Cancer, the survival outcome of patients with Burkitt lymphoma has improved substantially over the past decade, with notable exceptions. To help doctors and researchers better understand who responds well to treatment and who does not, the study...

lymphoma

FDA Grants Orphan Drug Status to Eisai’s Investigational Compound E7777 for Cutaneous T-Cell Lymphoma

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Eisai’s investigational compound E7777 for cutaneous T-cell lymphoma.  E7777 is designed to have an improved purity profile and manufacturing process. It is currently in a pivotal trial intended to support ...

lymphoma

Tositumomab/Iodine-131 Tositumomab Regimen for Non-Hodgkin Lymphoma to Be Discontinued

GlaxoSmithKline announced today that it will discontinue the manufacture and sale of the tositumomab/iodine-131 tositumomab (Bexxar) therapeutic regimen on February 20, 2014. Tositumomab/iodine-131 tositumomab is currently approved in the United States and Canada for the treatment of patients with ...

lymphoma

PET/CT Superior to Bone Marrow Biopsy for Diagnosis and Prognosis of Lymphoma Patients

A more precise method for determining bone marrow involvement in patients with diffuse large B-cell lymphoma—a key factor in tailoring patient management plans—has been identified by researchers in a study published in the August issue of The Journal of Nuclear Medicine. Imaging with...

lymphoma

Researchers Find Link Between Intestinal Bacteria and Lymphoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center (JCCC) have discovered that specific types of bacteria that live in the gut are major contributors to lymphoma. The study, led by Robert H. Schiestl, PhD, Professor of Pathology and Laboratory Medicine, Environmental Health Sciences, and...

lymphoma

Higher Incidence of Non-Hodgkin Lymphoma Found in Regions with Close Proximity to Benzene Release Sites

The incidence of a non-Hodgkin lymphoma (NHL) is significantly higher in regions near facilities that release the chemical benzene into the environment, according to a new study published early online in Cancer. This and other studies like it will be critical to identifying and enacting public...

leukemia
lymphoma

New Drug Application Submitted for Ibrutinib in the Treatment of Two B-cell Malignancies

Pharmacyclics, Inc, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational oral Bruton's tyrosine kinase inhibitor ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma (MCL) and...

lymphoma

Radioimmunotherapy/Chemotherapy Combination Could Extend Survival in Some Patients with Advanced Lymphoma

A new patient protocol for aggressive and recurrent lymphoma that combines intensive chemotherapy and radioimmunotherapy showed encouraging overall survival rates in some patients preparing for autologous bone marrow transplant, reported researchers at the 2013 Annual Meeting of the Society of...

lymphoma

Study Paves Way for Rational Drug Targeting of B-cell Lymphomas

A new study from Dana-Farber Cancer Institute may help clinicians and drug researchers choose the most promising genetic targets to attack in a common type of non-Hodgkin lymphoma. The report, published in the June 10 issue of Cancer Cellprovides a new, “big picture” view of an...

lymphoma

FDA Approves Lenalidomide for Patients with Relapsed or Refractory Mantle Cell Lymphoma

The U.S. Food and Drug Administration today approved lenalidomide (Revlimid) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (Velcade). Clinical Trial The approval was based on the results ...

lymphoma
multiple myeloma

Breaking News on Lymphoma and Myeloma to Be Reported at European Hematology Congress in Stockholm

In order to support high-quality science, the European Hematology Association collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research. In simultaneous sessions on Thursday, June 13, during the European...

lymphoma

ASCO 2013: Routine Surveillance Imaging Scans Add Little to Detection of Relapse in Patients with Diffuse Large B-cell Lymphoma

A large study reports that the vast majority of diffuse large B-cell lymphoma relapses are detected based on symptoms, abnormal blood tests or abnormal findings on physical exam, suggesting that CT scans, which are currently a routine part of follow-up, may be unnecessary. Researchers found that...

leukemia
lymphoma

Pharmacyclics Completes Enrollment of Phase III Ibrutinib CLL Study and Phase II Ibrutinib MCL Study

Pharmacyclics, Inc, announced today that the enrollment target of 350 patients for RESONATE, its phase III study using ibrutinib monotherapy vs ofatumumab (Arzerra) in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, was achieved on April 3, 2013. As...

lymphoma

NIH Trial Shows Promising Results in Treating Primary Mediastinal B-cell Lymphoma

Patients with primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to the mediastinum, had excellent outcomes, according to clinical trial results.  Until now, most standard treatment approaches for patients with this type of...

leukemia
lymphoma

Immunotherapy Showed Promising Antileukemia Activity in Pediatric Patients

Researchers using patients’ own immune cells in an immunotherapy approach called anti-CD19 chimeric antigen receptor (CAR) T-cell therapy achieved responses in children whose acute lymphocytic leukemia (ALL) had returned after a bone marrow transplant, according to preliminary results...

leukemia
lymphoma

Ibrutinib Receives Third Breakthrough Therapy Designation from the FDA

Pharmacyclics, Inc, announced today that the FDA has granted an additional Breakthrough Therapy Designation for the investigational oral agent ibrutinib as monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma with deletion of the short arm...

hematologic malignancies
leukemia
lymphoma

St. Jude Children's Research Hospital Announces Issuance of U.S. Patent for Genetically Modified Human Immune Cells for Cancer Therapy

The United States Patent and Trademark Office today awarded St. Jude Children's Research Hospital U.S. patent number 8,399,645 for its invention of compositions for genetically modifying human immune cells so they can destroy some of the most common forms of cancer in children and adults. "This...

lymphoma

Experimental Drug Combination Selectively Destroys Lymphoma Cells

Laboratory experiments conducted by researchers at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the investigational agent ibrutinib and bortezomib (Velcade) could potentially be an effective new therapy for several forms of blood cancer, including...

lymphoma

High-dose Vorinostat Effective at Treating Relapsed Lymphomas, Study Finds

Reporting the results of a phase I clinical trial to test the effectiveness of a new class of drugs to augment standard chemotherapy, a team led by Fred Hutchinson Cancer Research Center scientists found that giving patients high doses of vorinostat (Zolinza) in combination with another round...

Advertisement

Advertisement



Advertisement